Skip to main content
. Author manuscript; available in PMC: 2011 Feb 17.
Published in final edited form as: Adv Drug Deliv Rev. 2009 Nov 14;62(2):122–149. doi: 10.1016/j.addr.2009.10.004

Fig. 7.

Fig. 7

Long-circulating HPMA copolymer–DOX (P-DOX) conjugates of different molecular weight (Mw). (A) Chemical structure of HPMA copolymer–doxorubicin conjugate containing glycylphenylalanylleucylglycine side-chains and N2,N5-bis(N-methacryloylglycylphenylalanylleucylglycyl)ornithine crosslinker [104]; (B) concentration of DOX in OVCAR-3 carcinoma xenografts in nu/nu mice after i.v. bolus of free DOX or P-DOX of different Mw; (C) growth inhibition of s.c. human ovarian OVCAR-3 carcinoma xenografts in nu/nu mice by long-circulating P-DOX conjugates. The mice received i.v. injection of 2.2 mg/kg DOX equivalent dose as P-DOX of different Mw [85].